Abstract: Disclosed herein are heterocyclic compounds that inhibit the activity of FLT3. Also described are specific irreversible inhibitors of FLT3. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the FLT3 inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.

Abstract: Disclosed herein are macrocyclic compounds that inhibit the binding of KRas. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the KRas inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia, lung cancer, colorectal cancer, pancreatic cancer, and other diseases or conditions dependent on KRas interaction.

Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of KRas. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the KRas inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia, lung cancer, colorectal cancer, pancreatic cancer, and other diseases or conditions dependent on KRas interaction.

Abstract: Disclosed herein are heterocyclic compounds that inhibit the activity of FLT3. Also described are specific covalent inhibitors of FLT3. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the FLT3 inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.

Abstract: Disclosed herein are heterocyclic compounds, for example, according to the following formula and analogs thereof: that inhibit the activity of FLT3. Also described are specific covalent inhibitors of FLT3. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the FLT3 inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.

Abstract: Disclosed herein are heterocyclic compounds that inhibit the activity of FLT3. Also described are specific covalent inhibitors of FLT3. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the FLT3 inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.

Abstract: The present invention relates to novel hair treatment materials, and in particular materials for shaping hair and/or strengthening the hair. Also described are the use of these compounds in hair care formulations for shaping, straightening, strengthening or treating the hair, and the use of the compounds for hair straightening and/or hair strengthening.

Abstract: The present invention relates to novel hair treatment materials, and in particular materials for shaping hair and/or strengthening the hair. Also described are the use of these compounds in hair care formulations for shaping, straightening, strengthening or treating the hair, and the use of the compounds for hair straightening and/or hair strengthening.

Abstract: A hair care composition comprising: i) at least one crosslinked nonionic amphiphilic suspending polymer; ii) at least one anionic surfactant; iii) at least one particulate antidandruff agent; and iv) water. The suspending polymer is a pH independent nonionic, amphiphilic emulsion polymer that is crosslinked with an amphiphilic crosslinking agent and effectively suspends water insoluble particulate antidandruff agents.

Abstract: A hair conditioning composition comprising: a) at least one cationic surfactant compound; b) at least one fatty acid ester of an ethoxylated alkyl glucoside; c) at least one nonionic, amphiphilic, emulsion polymer; d) an aqueous carrier; and optionally, e) at least one other auxiliary conditioning agent different than (a) said other conditioning agent is selected from a silicone, a hydrocarbon oil, a natural oil, an ester oil, a cationic compound, a cationic polymer, and combinations thereof.

Abstract: A hair care composition comprising: i) at least one suspending polymer; ii) at least one anionic surfactant; iii) at least one particulate antidandruff agent; and iv) water. The suspending polymer is a pH independent nonionic, amphiphilic emulsion polymer that effectively suspends water insoluble particulate antidandruff agents.

Abstract: A composition and a process for straightening hair are disclosed. The process includes coating keratin fibers with a composition comprising a thermally-activated agent and a guanidine moiety containing adjuvant compound and contacting the coated keratin fibers with a heating device at a temperature of at least 185 C for sufficient time to modify the keratin fibers.

Abstract: A protein-acrylate copolymer contains at least one nitrogen containing acrylic monomer. The nitrogen containing acrylic monomer preferably contains a tertiary or quaternary amine group, and particularly a quaternary amine group. The protein-acrylate copolymer can be produced by reacting hydrolyzed protein with at least one nitrogen containing acrylic monomer, preferably by free-radical polymerization. The protein-acrylate copolymer is suitable for use in personal care or cosmetic products, particularly in hair care products where it can increase volume to hair.

Abstract: A protein-acrylate copolymer contains at least one nitrogen containing acrylic monomer. The nitrogen containing acrylic monomer preferably contains a tertiary or quaternary amine group, and particularly a quaternary amine group. The protein-acrylate copolymer can be produced by reacting hydrolysed protein with at least one nitrogen containing acrylic monomer, preferably by free-radical polymerisation. The protein-acrylate copolymer is suitable for use in personal care or cosmetic products, particularly in hair care products where it can increase volume to hair.

Abstract: A magnetic heater is provided having a conductive member and a first magnet assembly comprising a frame and at least one magnet disposed a distance adjacent the conductive member, wherein the first magnet assembly and the first frame are adapted to rotate relative to each other about an axis so as to induce eddy currents in the conductive member when relative motion is produced between the conductive member and the first magnet assembly, the at least one magnet adapted to move relative to the frame in dependence on the change in the rate of rotation of the frame. The magnetic heater is provided with a passive relative-positioning actuator adapted to move one or more magnets in an axial direction and a radial direction relative to the frame. Such movement is exploited to control the magnetic field strength at the conductive member by controlling, among other things, the conductor/magnet spacing.

Abstract: A method of treatment using a compound of Formula I: 1

Abstract: An apparatus and method for generating heat, in particular for heating a fluid. The apparatus includes a frame, with at least one permanent magnet fixedly mounted to the frame. An electrically conductive member is disposed proximate the permanent magnets. The magnetic field of the magnets upon the conductive member is made to vary cyclically. Typically either the permanent magnets, the conductive member, or both are movable with respect to one another. Relative motion of the conductive member and the magnets causes the magnetic field experienced by the conductive member to vary, which causes it to become hot. The total heat energy generated in the conductive member may exceed the total energy applied to the apparatus to produce the varying magnetic field. The apparatus may include a fluid path proximate the conductive member. Fluid in the fluid path receives heat from the conductive member.

Abstract: Invented is an improved process for preparing aromatic ring-fused cyclopentane derivatives. Preferred compounds prepared by this invention are indane carboxylates and cyclopentano[b]pyridine derivatives. The most preferred compounds prepared by this inventino are (+)(1S, 2R, 3S)-3-[2-(2-hydroxyeth-1-yloxy)-4-methoxyphenyl]-1-(3,4-methylenedioxyphenyl)-5-(prop-1-yloxy)indane-2-carboxylic acid and pharmaceutically acceptable salts thereof and (+)(1S, 2R, 3S)-3-[(2-carboxymethoxy-4-methoxyphenyl)-1- (3,4-methylenedioxyphenyl)-5-(prop-1-yloxy)indane-2-carboxylic acid and pharmaceutically acceptable salts thereof. Also invented are novel intermediates useful in preparing these compounds.

Abstract: A method of treatment using a compound of Formula I: wherein: R1 is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl; R2 is hydrogen, lower alkyl of up to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl and phenylpropyl; R3 is hydrogen or lower alkyl of up to 6 carbon atoms; R4 is hydrogen or lower alkyl of up to 6 carbon atoms, or when X is oxygen, R4 together with R5 can represent —CH2—O—; X is a valency bond, —CH2, oxygen or sulfur; Ar is selected from phenyl, naphthyl, indanyl and tetrahydronapthyl; R5 and R6 are individually selected from hydrogen, fluorine, chlorine, bromine, hydroxyl, lower alkyl of up to 6 carbon atoms, a —CONH2— group, lower alkoxy of up to 6 carbon atoms, benzyloxy, lower alkylthio of up to 6 carbon atoms, lower alkysulphinyl of up to 6 carbon atoms and lower alkylsulphonyl of up to 6 carbon atoms; or R5 and R6 together represent methylenedioxy; or a pharmaceutically acceptable salt thereof, alone or in conjunction w

Abstract: A method of treatment using carvedilol is disclosed, wherein the carvedilol decreases the risk of mortality caused by congestive heart failure in patients. The patients are titrated with low amounts of carvedilol, with the initial titration dosage being only 10 to 30% of the daily maintenance dose.